Long-term follow-up of patients having false-positive multitarget stool DNA tests after negative screening colonoscopy: The long-haul cohort study

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 4, 2017, Pages 614-621

  Cotter, Thomas G ^a   Burger, Kelli N ^a   Devens, Mary E ^a   Simonson, Julie A ^a   Lowrie, Kari L ^a   Heigh, Russell I ^b   Mahoney, Douglas W ^a   Johnson, David H ^a   Ahlquist, David A ^a   Kisiel, John B ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; OSTEOGENIN; VIMENTIN; DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA DETERMINATION; FALSE POSITIVE RESULT; FECES ANALYSIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY RATE; MULTITARGET STOOL DNA TEST; PATIENT REFERRAL; PRIORITY JOURNAL; SEX DIFFERENCE; CASE CONTROL STUDY; CHEMISTRY; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; FECES; GENETICS; MASS SCREENING; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85017032282     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0800     Document Type: Article

References (34)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17.
2. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
3. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
4. Nishihara R, Ogino S, Chan AT. Colorectal-cancer incidence and mortality after screening. N Engl J Med 2013;369:2355.
5. U. S. Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016; 315:2564-75.
6. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104: 739-50.
7. American Cancer Society. Colorectal cancer prevention and early detection. Atlanta, GA: American Cancer Society; [updated 2016 Apr 24]. Available from: http://www. cancer. org/cancer/colonandrectumcancer/moreinformation/ colonandrectumcancerearlydetection/colorectal-cancer-earlydetection-screening-tests-used.
8. National Committee for Quality Assurance (NCQA). HEDiS-1 2017 Volume 2: Technical Update. Washington, DC: National Committee for Quality Assurance; [updated 2016 Oct 3]. Available from: http://www. ncqa. org/Portals/0/HEDiSQM/HEDiS2017/HEDiS%202017%20Volume %202%20Technical%20Update. pdf?ver2016-10-03-114902-317.
9. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. NEngl J Med 2014;370:1287-97.
10. Redwood DG, Asay ED, Blake ID, Sacco PE, Christensen CM, Sacco FD, et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people. Mayo Clin Proc 2016;91:61-70.
11. Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 2013;11:1313-8.
12. Ahlquist DA, Zou H, Domanico M,Mahoney DW, Yab TC, Taylor WR, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142:248-56.
13. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right-and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010;102: 89-95.
14. Kahi CJ,Hewett DG, Norton DL, EckertGJ, Rex DK. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol 2011;9:42-6.
15. Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Gregg S, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene 2004;23:3521-9.
16. Liu Z, Zhang J, Gao Y, Pei L, Zhou J, Gu L, et al. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. Clin Cancer Res 2014;20:4598-612.
17. Hashimoto D, Arima K, Yokoyama N, Chikamoto A, Taki K, Inoue R, et al. Heterogeneity of KRAS mutations in pancreatic ductal adenocarcinoma. Pancreas 2016;45:1111-4.
18. Exact Sciences Corporation. Summary of Effectiveness and Safety Data. Silver Spring, MD: U. S. Food and Drug Administration; 2014. Available from: http://www. accessdata. fda. gov/cdrh-docs/pdf13/P130017b. pdf.
19. Ahlquist DA, Sargent D, Loprinzi CL, Goldberg RM, Rex DK, Levin TR, et al. False-positive stool DNA results on colorectal cancer screening yield from supracolonic evaluation. Gastroenterology 2004;126:A-58.
20. American Academy of Family Physicians. Clinical Preventive Service Recommendation: Colorectal Cancer. Leawood, KS: American Academy of Family Physicians; [updated 2016 Aug 31]. Available from: http://www. aafp. org/patient-care/clinical-recommendations/all/colorectal-cancer. html.
21. Ahlquist DA, Taylor WR, Yab TC, Devens ME, Mahoney DW, Boardman LA, et al. Aberrantly methylated gene marker levels in stool: Effects of demographic, exposure, body mass, and other patient characteristics. J Mol Biomark Diagn 2012;3:133.
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7.
23. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Incidence-SEER 9 Regs Research Data, Nov 2014 Sub (1973-2012). Bethesda, MD; NIH. Available from: https://seer. cancer. gov/ data/seerstat/nov2014/.
24. U. S. Preventive Services Task Force. Final Recommendation Statement: Lung Cancer: Screening. Bethesda, MD; U. S. Preventive Services Task Force; [Updated Oct 2014]. Available from: https://www. uspreventiveservicestaskforce. org/Page/Document/RecommendationStatementFinal/lungcancer-screening.
25. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-47.
26. Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, et al. Quality indicators for colonoscopy. Am J Gastroenterol 2015;110:72-90.
27. Hubbard RA, Johnson E, Hsia R, Rutter CM. The cumulative risk of falsepositive fecal occult blood test after 10 years of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2013;22:1612-9.
28. Allard J, Cosby R, Del Giudice ME, Irvine EJ, Morgan D, Tinmouth J. Gastroscopy following a positive fecal occult blood test and negative colonoscopy: systematic review and guideline. Can J Gastroenterol 2010;24:113-20.
29. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954-61.
30. Haug U, Knudsen AB, Kuntz KM. How should individuals with a falsepositive fecal occult blood test for colorectal cancer be managed?Adecision analysis. Int J Cancer 2012;131:2094-102.
31. Johnson D, Kisiel JB, Burger KN, Mahoney DW, Devens ME, Ahlquist DA, Sweetser S. Knowledge of a positive Cologuard-result improves yield and quality of colonoscopy. Gastroenterology 2016;150:S454.
32. Kisiel JB, Ahlquist DA. Stool DNA screening for colorectal cancer: opportunities to improve value with next generation tests. J Clin Gastroenterol 2011;45:301-8.
33. Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: Modeling study for the US preventive services task force. JAMA. 2016;315:2595-609.
34. Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology 2016;151:427-39.